New PET scan for cancer using CD73 probe
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new PET imaging agent that targets CD73, a protein found on many cancer cells. It may help doctors see tumors more clearly without chemotherapy or radiation before the scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and expected to live at least 12 more weeks.
- You have not had chemotherapy or radiation therapy recently, and you are able to have a biopsy or surgery to confirm your cancer type.
- You have at least one tumor that can be measured on a standard scan (RECIST 1.1).
- You are willing to give written consent and can come for follow-up visits.
- You do not have severe liver or kidney problems, and if you are a woman of childbearing potential, you agree to use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
This early-phase trial tests a new imaging probe that targets a protein called CD73 on cells. It helps doctors see how the probe works in your body and if it could be used for diagnosis in the future.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This trial uses a special PET scan with a new tracer called 68Ga-DOTA-BLP to spot cancer and its spread in the body. It aims to see if this scan can find tumors in lymph nodes or other areas without needing more painful biopsies.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
Hear when a new Tumor Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.